We recently cloned a protective antigen that is commonly expressed in Ascaris species that infect humans and pigs. We evaluated the vaccinal effects of this 16-kilodalton protein (As16) in pigs, the natural host of Ascaris suum, by intranasal immunization. Pigs that received Escherichia coli-expressed recombinant As16 (rAs16) coupled with cholera toxin (CT) had significantly elevated levels of rAs16-specific serum immunoglobulin G (IgG) and mucosal-associated IgA antibodies. rAs16 evoked a type II immune response characterized by elevated levels of interleukin-4 and -10 in the culture supernatants of peripheral blood mononuclear cells of the vaccinated pigs. An increased level of rAs16-specific serum IgG1 was also detected. Pigs vaccinated with rAs16-CT were protected from migration of A. suum larvae through the lungs, as indicated by a 58% reduction in the recovery of lung-stage third-stage larvae (L3), compared with that in nonvaccinated controls. Purified immunoglobulin from rAs16-CT-vaccinated pigs inhibited survival of infective L3 and interrupted the molting of lung-stage L3. Immunofluorescence studies revealed that this immunoglobulin bound to the digestive tracts of L3, suggesting that it might inactivate functions of the gut tissues of Ascaris species. We conclude that rAs16 is a promising mucosal vaccine candidate for pig and human ascariasis.
the 2 species of parasites on morphological, immunological, and biochemical bases, species discrimination between A. lumbricoides and A. suum has been controversial [6] [7] [8] . It has recently been suggested that human and swine Ascaris species reproduce in a closed population [9] . The control of pig ascariasis may thus be required for advancing measures to decrease human ascariasis.
Prior studies have shown that pigs can be rendered immune to A. suum infection by immunization with radiation-attenuated infective larvae or by chemically abbreviated infection [10] [11] [12] [13] . In mice, passive transfer of serum from immune mice is effective for larval killing and the prevention of stunting [14] . Crude larval antigens can induce protective immunity, suggesting that larval stages possess protective antigen against A. suum infection. In recent vaccine strategies, mucosal immunization is a critical goal in the development of vaccines against intestinal pathogens. Bacterial toxins such as cholera toxin (CT) are now available as mucosal adjuvants [15] , and CT can induce antigen-specific sys-temic and mucosal responses in both humans [16, 17] and livestock [18] [19] [20] .
We recently identified a potent protective 16-kDa antigen (As16) that is shared by both the human and pig roundworms and, of interest, has no similarity to mammalian proteins but has some similarity to proteins of the filarial parasites and to a Caenorhabditis elegans gene product. These properties may prevent As16 from inducing an autoimmune response when used for vaccination, because parasite-specific gene products should induce minimal risk of cross-reaction with host constituents [21] . Furthermore, As16 has shown to evoke a mixed (both type I and type II) type of immune response and to confer appreciable protection against A. suum challenge infection in an A. suum-permissive mouse infection model [22] . These findings provide an excellent opportunity to evaluate the biological significance of rAs16 protein in Ascaris roundworms and the potential of this protein as a vaccine against A. suum infection in a larger animal model (e.g., pigs, the natural host of the parasite).
In the present study, we immunized pigs by the mucosal route intranasally (inl) with purified rAs16, followed by 2 booster injections, and evaluated its vaccinal effects against A. suum challenge infection, the type of immune response, and the probable biological functions of the proteins in larval-stage worms. We examined the effect of rAs16-specific immunoglobulin from pigs immunized with rAs16 on larval survival and the molting process. We found that rAs16 induced a type II immune response characterized by elevated levels of interleukin (IL)-4 and IL-10. High titers of rAs16-specific mucosal IgA and serum IgG antibody were also seen in the vaccinated pigs. Of interest, pigs immunized inl showed an appreciable protection against larval migration after challenge with A. suum embryonated eggs. More important, we discuss the postulated inhibitory effects of rAs16-specific immunoglobulin antibody (pIg-rAs16) obtained from protectively immune pigs against larval development and/or molting in an in vitro larval culture system.
MATERIALS AND METHODS

Pigs.
Six-week-old crossbred piglets (Landrace ϫ Whitelarge ϫ Duroc) from a pathogen-free colony were used for vaccination and challenge infection studies. Animal experiments were approved by the National Institute of Animal Health Animal Care and Use Committee (approval no. 361).
Parasites. Adult A. suum were obtained from infected pigs at a slaughterhouse in Shimotsuma, Japan. Unembryonated and embryonated eggs were obtained essentially as described elsewhere [22] . Infective third-stage larvae (L3) for in vitro culture were obtained as described elsewhere [23] . The lung-stage L3 used for immunohistochemical analyses and in vitro cultures were obtained from the lungs of infected pigs used in the vaccination studies, as described below.
Recombinant As16 protein.
Recombinant As16 protein was prepared as described elsewhere [22] . The entire coding region of As16 except the signal sequence was subcloned into a plasmid expression vector, pTrcHisB (Invitrogen). The plasmid was transformed into Escherichia coli strain TOP10F (Invitrogen), and the purification process was monitored by SDS-PAGE with use of a T7 Taq monoclonal antibody (Novergen). The recombinant protein was purified with use of AKTA equipped with a HiTrap chlelating HP column (Amersham Pharmacia Biotech). Histidine-tagged As16 was dialyzed against PBS in an Aside-A-Lyzer Dialysis Cassette (Pierce).
Vaccination and challenge infection. Recombinant As16 was coupled with CT (C-8052; Sigma) by conjugation in darkness at 4ЊC for 16 h. Nine pigs were divided into 3 groups. The rAs16-CT-immunized group was inoculated inl with 500 mg of rAs16 coupled with 25 mg of CT in a volume of 1 mL of PBS (0.5 mL/nostril). On day 21, a booster inoculation of 300 mg of rAs16 coupled with 15 mg of CT was given. The final boost of 300 mg of rAs16 coupled with 15 mg of CT was given on day 35. The second and third groups were inoculated with the same dose of CT or rAs16 alone, respectively, on the same days as the immunized group. One week after the final immunization, pigs were inoculated orally with 10 4 A. suum embryonated eggs. During immunization, blood and nasal swab samples were collected at various time points to monitor antirAs16 antibodies. The swabs were mixed with 500 mL of PBS containing a protein inhibitor cocktail (Complete; Boehringer Mannheim) and vortexed, the mixture was centrifuged at 26,000 g for 60 min at 4ЊC, and the supernatant was stored at Ϫ80ЊC. The pigs were killed on day 7 as follows: pigs were lightly anesthetized with a combination of ketamine hydrochloride and xylazine mixed in the same syringe and given intramuscularly. After they lay down in the pen, the pigs were heavily anesthetized with pentobarbital and killed by bleeding. Their lungs were removed and minced with a surgical knife, and larvae were recovered by use of a Baermann technique [24, 25] and counted under a microscope. The small intestine was removed and put on an ice pack, and mucous tissues were removed with a surgical knife. The mucosal tissues were placed in an equal volume of PBS containing a protein inhibitor cocktail and vortexed until the tissues were disrupted. The tissue mixture was centrifuged at 26,000 g for 60 min at 4ЊC, and the supernatant was stored at Ϫ80ЊC.
Cytokine assay. Pig peripheral blood mononuclear cells (PBMCs) were isolated from heparinized venous blood by isolating the buffy coat and eliminating erythrocyte contamination by use of a Lymphoprep (Axis-Shield) density gradient. After the PBMCs were washed with PBS, they were suspended in RPMI 1640 medium supplemented with 10% (vol/vol) heatinactivated fetal calf serum, 10 mmol/L HEPES buffer, 0.2 mmol/L l-glutamine, and 5 mg/mL gentamicin. They were cul- tured at 37ЊC in 5% CO 2 in 24-well plates at a final concentration of cells in a final volume of 1.0 mL/well. The 6 4 ϫ 10 cells were stimulated with 5 mg/mL rAs16 for 48 h, and the culture supernatant was stored at Ϫ80ЊC. Cytokine analysis was done with a sandwich ELISA kit (Biosource International) for IL-4, IL-10, and interferon (IFN)-g, according to the manufacturer's protocol.
Antibody assays. Measurement of mucosal IgA, serum IgG, and IgG subclass-specific antibody to rAs16 was done by ELISA. For IgA and IgG, pig IgA and IgG quantitation kits (Bethyl), respectively, were used as recommended by the manufacturer. For IgG subclass responses, mouse monoclonal anti-porcine IgG1 and IgG2 (Serotec) and horseradish peroxidase-conjugated goat anti-mouse IgG (Bethyl Laboratories) were used. The end point titer was determined as the reciprocal log 2 of the last dilution that gave an optical density at 405 nm higher than the value of the negative control samples.
Localization of endogenous As16 in the A. suum larval stages. Lung-stage L3 were fixed in 4% paraformaldehyde in 0.1 mol/L phosphate buffer and processed for immunohistochemical analysis, as described elsewhere [26] .
Immunoglobulin purification. In vitro L3 culture. Infective and lung-stage A. suum L3 were used for in vitro culturing to examine whether pIg-rAs16 blocks survival and development of the larval-stage parasites. The larvae were suspended in RPMI 1640 medium supplemented with 10% (vol/vol) fetal bovine serum and 50 mg/mL penicillin/streptomycin and were cultured in 96-well flat-bottomed tissue culture plates, as described elsewhere [26] . The cultures were incubated at 37ЊC in a humidified 5% CO 2 incubator in the presence of pIg-rAs16. Immunoglobulins from pigs vaccinated with CT and rAs16 alone were used as controls. These serum samples were obtained on the day of challenge infection. Larval viability and morphological changes were examined under a microscope.
Immunofluorescence. Cultured larvae (infective and lungstage L3) were fixed with acetone for 5 min and rinsed several times with cold PBS. Samples were incubated with fluorescein isothiocyanate-labeled goat anti-pig IgG (Bethyl) for 15 min, rinsed with cold PBS, and then covered with cover slips and observed under an Axiophot fluorescence microscope (Carl Zeiss).
Statistical analysis. Data are expressed as for mean ‫ע‬ SD the experimental groups. Comparisons between groups were done with the 2-tailed Student's t test.
RESULTS
Antibody response against rAs16 in vaccinated pigs. We previously described the expression of rAs16 in E. coli [22] . To obtain a large amount of the recombinant protein, we collected E. coli-expressed As16 and purified it by high-pressure liquid chromatography. The purified protein was 99% pure as judged by the electrophoretic profile of the high-pressure liquid chromatography-purified fraction (figure 1) and was used for a vaccine trial in pigs. The doses of rAs16 and CT were based on previous reports [20, 22] . No clinical symptoms were found in any of the immunized pigs during the period from the first vaccination until the challenge infection. For the initial value, we examined the rAs16-specific IgG titer in the vaccinated pigs before challenge infection with A. suum embryonated eggs. A significantly elevated rAs16-specific IgG titer in serum was found in pigs immunized with rAs16-CT (figure 2A). We measured the levels of rAs16-specific IgA antibodies in the nasal fluid. As shown in figure 2B , a marked rAs16-specific IgA response in nasal fluid was noted. No detectable anti-As16 IgA antibody responses in nasal fluid or anti-As16 IgG antibody responses in serum samples were seen in pigs vaccinated with rAs16 alone or CT alone. Furthermore, we examined rAs16-specific serum IgG subclass responses. All of the titers of rAs16-specific IgG subclasses were significantly higher in pigs vacci- Cytokine responses. To assess T cell responses to the rAs16 molecule in vaccinated pigs, we examined cytokine secretion by rAs16-stimulated PBMCs. As shown in figure 4, rAs16 evoked significantly elevated levels of IL-4 and IL-10 in the rAs16-CTvaccinated pigs. The release of IFN-g was not significantly higher in pigs immunized with rAs16-CT than in pigs receiving CT alone or rAs16 alone. These data suggest that rAs16 induces a type II immune response in pigs.
Vaccinal effects. After we confirmed the induction of rAs16-mediated immune responses, the vaccinated pigs were challenged with 10 4 embryonated eggs of A. suum. At autopsy, a number of milk spot formations were seen in the livers of all vaccinated pigs, but no significant differences were found between rAs16-CT-vaccinated pigs and pigs that were given rAs16 or CT alone. Pinpoint hemorrhages in the lungs were clearly decreased in rAs16-CT-vaccinated pigs, suggesting that the numbers of lungstage L3 were diminished. Pigs that were vaccinated with rAs16-CT and received 2 booster doses at a 2-week interval were protected from migration of A. suum larvae after challenge infection, as indicated by a 58% reduction in the recovery of lung-stage L3 ( , recovered larvae), compared with mean ‫ע‬ SD 891 ‫ע‬ 201 pigs that received either rAs16 (1873 ‫ע‬ 398 recovered larvae) or CT ( recovered larvae) alone. We examined the 2099 ‫ע‬ 344 rAs16-specific IgA and IgG antibody responses in the small intestine and serum, respectively, at autopsy. The antibody titer of rAs16-specific mucosal IgA in rAs16-CT-immunized pigs was significantly higher than that in the groups receiving rAs16 or CT alone, suggesting that the rAs16-CT conjugate induced the production of rAs16-specific IgA (figure 5). At the same time, a higher titer of rAs16-specific serum IgG antibody was detected in rAs16-CT-vaccinated pigs.
Endogenous form of As16 localized in the digestive tract of A. suum larval stages. To determine the tissue localization of the endogenous form of As16 in A. suum migratory stages, the reaction with serum from pigs vaccinated with rAs16-CT (1:50) was examined in infective and lung-stage L3 by immunohistochemical analysis. The antibody bound to the esophagus and interior and posterior portions of the intestine, suggesting that endogenous As16 was expressed throughout the gut tissues (figure 6). A part of the hypodermis also reacted with the antibody.
Inhibition of larval development by immunoglobulin from pigs vaccinated with rAs16-CT. To assess the effect of pIgrAs16 on the survival and development of A. suum tissue migratory stages in pigs, infective and lung-stage L3 were cultured in the presence of pIg-rAs16. As shown in figure 7 , the development of cultured infective L3 was significantly inhibited by the pIg-rAs16 at 100 ng/mL, and the bound antibody was localized in the digestive tract, including the esophagus, intestine, and part of the hypodermis ( figure 8A-D) . Inhibition of the survival of infective L3 was found to be concentration-dependent. Of interest, molting of lung-stage L3 to the 4th-stage lar- for each group. Each sample was examined in triplicate. mean ‫ע‬ SD * and ** , mean value was significantly higher than that of P ! .05 P ! .01 the group immunized with CT alone. vae (L4) was almost completely inhibited at a concentration of pIg-rAs16 similar to the concentration that interfered with the survival and development of infective L3 (figure 9; figure 8E-H), although the pIg-rAs16 did not significantly affect the viability of lung-stage L3 at any concentration used (data not shown). The degree of inhibition of molting was also concentration dependent. These results suggest that As16 protein may play an important role in the development and molting process of Ascaris roundworms.
DISCUSSION
Identifying the immunoreactive antigens that induce protection against the parasitic nematodes in the natural host has become an important goal for controlling parasitic infectious diseases. In recent years, vaccine studies and the understanding of hostparasite interactions that lead to particular categories of the adaptive immune response have been greatly accelerated by using immunogenic molecules cloned from Schistosoma species and filarial parasites, with permissive hosts used as animal models. Although permissive hosts allow infection with the parasites, the complete life cycle of the parasites is not always achieved, depending on the host specificity, which limits our understanding of host-pathogen interactions that are likely to occur in the natural hosts. Considering this fact, we evaluated the vaccinal effects of As16 protein on the immune phenotype in larger animal hosts and demonstrated the involvement of this protein in parasite survival and development in vitro. We previously demonstrated that vaccination of mice with rAs16 can induce protection against A. suum infection when the immunogen is delivered via the mucosal route with use of CT B subunit as a mucosal adjuvant [22] . However, those findings were obtained in a permissive host, but not in pigs, the natural In vitro antilarval activity of recombinant 16-kDa Ascaris suum protein (rAs16)-specific immunoglobulin antibody obtained from protectively immune pigs (pIg-rAs16). Infective third-stage larvae (L3) were cultured in RPMI 1640 medium containing pIg-rAs16 at 100 ng/mL (A) or 50 ng/mL (B) or purified immunoglobulins from pig vaccinated with rAs16 or cholera toxin (CT) alone, with the concentration adjusted to match that of pIg-rAs16. Data are for each group. Each sample mean ‫ע‬ SD was examined in triplicate. ** and *** , mean value was P ! .01 P ! .001 significantly different from that of the groups incubated with serum from pigs vaccinated with rAs16 or CT alone.
host of A. suum. In the present study, we administered rAs16-CT inl to assess the vaccinal efficacy of rAs16 in pigs. The vaccinated pigs produced rAs16-specific serum IgG antibody and mucosal IgA antibody responses at the site of the infection and were protected against the larval migration of the A. suum tissue phase. Numerous reports have shown that pigs acquire protective immunity against A. suum infection after immunization with the larval stages [12, 13] . In addition, although pigs have been reported to be immunized with cuticle antigens or excretory and secretory (ES) products from larval stages, no antigenic molecule inducing protection against A. suum challenge infection was hitherto identified [27, 28] . Thus, rAs16 is the first antigen to be demonstrated to confer protection against A. suum infection in pigs.
Infection with A. suum is established orally by infective L3 after their development from embryonated eggs. The infective L3 invade into the small intestine of the host, migrate into the liver and the lung, and finally reach the small intestine, where they develop into adult worms. Therefore, protective immunity to A. suum infection may involve systemic host defenses, as well as local immunity. In particular, mucosal immunity in the small intestine is critical to infection. In the present study, we chose CT as a mucosal adjuvant because it is one of the most powerful mucosal adjuvants known [29] [30] [31] [32] . Pigs that received rAs16-CT via inl immunization successfully produced high titers of rAs16-specific mucosal IgA and serum IgG antibodies, suggesting that vaccination with rAs16-CT induced both local and systemic immunity in the present study.
Pigs vaccinated with rAs16-CT had a high level of anti-rAs16 IgG1 antibody, suggesting that rAs16-CT vaccination resulted in a type II immune response against rAs16 [33, 34] . In fact, immunization elicited marked production of IL-4 and IL-10, the markers of the type II cytokine response in pigs [35] . CT induces a type II-biased immune response in mice and humans, in which IgG1 production indicates the potential for antibodydependent, cell-mediated cytotoxicity [36] . The life cycle of ascarid parasites involves 2 different phases, consisting of the larval and adult stages. Specific events in these 2 phases may provoke different host immune responses against the larval stages in the tissues and the adult worms in the small intestine of the natural host. Recently, it was demonstrated that larvae in the tissue migratory phase, which occurs between infective and lung-stage L3, could induce protective immunity against A. suum infection but not against adult worms in pigs [37] . A number of cytokine responses have been examined as potential markers of cellular immune responses in helminth infections to investigate the mechanism of protective immunity against the parasites in human or mouse models [38, 39] . At present, the available cytokine markers in pigs are very limited, and no studies have investigated parasite-specific cellular responses to A. suum infection in pigs. It has been reported that a highly polarized type II cytokine response occurs in areas where human ascariasis is endemic [40] . This finding suggests a mechanism of protective immunity against human A. lumbricoides infection, because people can acquire resistance to reinfection.
Studies of pigs immunized with rAs16-CT may provide insight into the cytokine responses involved in host resistance against Ascaris infection.
A variety of parasitological criteria have been reported for assessing the reduction of worm burden following immunization in vaccine trials of candidate vaccine molecules for parasitic infectious diseases [41, 42] . In the present study, we counted the number of larvae that reached the lungs and showed that vaccinated pigs had a significant reduction in larval number, suggesting that rAs16 is capable of inducing protective immunity against A. suum infection. However, for helminthic parasites with a complex life cycle, the size of worms and daily egg production or fecundity are also considered to be important criteria for the judgment of vaccinal efficacy [43, 44] . Studies of other parasitological criteria, in addition to the reduction of lung-stage L3, should be done to clarify the vaccinal effects of rAs16 in pigs. Of interest, a recent study demonstrated that parasite vaccine molecules may exert therapeutic effects and not merely induce protective immunity, as was once believed [45] .
We speculated that pig anti-rAs16 antibodies may damage gut tissues of A. suum larvae. To test this possibility, we examined the effect of pIg-rAs16 against the tissue migratory larvae by use of an in vitro culture system. Our findings clearly showed that pIg-rAs16 was capable of interfering with larval survival; thus, such interference may be crucial in inhibiting invasion of the parasite into the organs and tissues of pigs. The survival of infective L3 was inhibited by pIg-rAs16 in a concentration-dependent manner. More than half of the infective L3 population was killed in the presence of 100 ng/mL pIg- rAs16 during this experiment. We assume that As16 is abundantly expressed during the development of A. suum larvae toward adult worms in the host [21] . Actually, we estimated the concentration of rAs16-specific IgG antibody in rAs16-CTimmunized pigs on the day of challenge infection to be ∼80 ‫ע‬ 38 ng/mL. If the role of this protein is essential to A. suum survival, neutralization by the immune response may be sufficient to induce protection in pigs [21] .
It is well known that the larval ES products are involved as potential vaccine molecules against A. suum infection [28] . In the present study, immunofluorescence analysis suggested that the target organ of pIg-rAs16 was the digestive tract of A. suum. The endogenous As16 is originally found as ES products in all A. suum life stages [22] . Parasite ES products are thought to have important roles in parasite maintenance and survival, including roles in host invasion, reproduction, and host antiparasite immune responses [46] [47] [48] . pIg-As16 may inactivate the biological function of this ES product expressed in the gut of A. suum larvae.
Of interest, pIg-As16 blocked molting from lung-stage L3 to L4, a process likely to be essential to the success of parasitism. As16 was recently shown to be localized in the hypodermis and intestine of adult worms [22] . As16 was found to be localized in the digestive tract of larval stages in the present study. It is thought that pIg-As16 neutralizes As16 antigen expressed in larval parasites and leads to an antibody-mediated inactivation of the larvae. Molting of nematode parasites is a complex process, and very little is known about its molecular mechanisms. pIg-As16-mediated inhibition of molting of A. suum larvae is not clear in the present study. It is assumed that As16 protein may be involved in the complex process of molting, and its neutralization by antigen-specific antibody may lead to the interference with the molting process. The neutralizing efficiency of pIg-As16 was found to differ depending on the stage of larval parasites (e.g., infective vs. lung-stage larvae). We hypothesize that neutralization by antigen-specific antibody more efficiently occurs in infective-stage larvae, because they were entirely inactivated, and thereby exerts a parasiticidal effect, suggesting that these stages are more vulnerable than are lungstage larvae because the latter stages are partially resistant. When adult worms were incubated in the presence of 100 ng/ mL pIg-rAs16, we did not find any morphological changes, suggesting that very little or no neutralization of the target protein occurs in the adult stage.
In addition, because the mucosal surface of the small intestine is the initial site of A. suum infection, it is important to establish protective immunity there. It has been reported that administration of A. suum L3 to animals results in induction of an A. suum L3-specific IgA response in the small intestine [49] . Studies of whether rAs16-specific IgA antibody affords protection against A. suum infection would allow us to determine whether rAs16 can induce protective immunity against A. suum infection.
In conclusion, we have demonstrated that inl vaccination of pigs with rAs16 protects the host against larval migration of A. suum via rAs16-specific immunoglobulin antibodies. Recent studies have shown that A. lumbricoides and A. suum are very closely related and are capable of cross-infecting both humans and pigs [4, 5, 9] . We anticipate that rAs16 will contribute to the ongoing development of mucosal vaccines against Ascaris species for human and veterinary uses.
